person · Reporting owner

Dineen John M.

Disclosed activity across 4 companies

Tapewire entity: 11199
SEC CIK: 0001645270

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
COGNIZANT TECHNOLOGY SOLUTIONS CORPCTSH · Entity 473	Director	August 25, 2026	August 27, 2026
LAM RESEARCH CORPLRCX · Entity 1467	Director	November 07, 2025	November 10, 2025
MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770	Director	June 13, 2018	June 15, 2018

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

COGNIZANT TECHNOLOGY SOLUTIONS CORP

Report date August 25, 2026 · Filed August 27, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	20,464.4423	Reported balance After 2026-08-25 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-08-25 · Grant · Acquired 106.5353 · Balance 20,464.4423 F1: Reflects restricted stock units received pursuant to dividend equivalent rights accrued on previously outstanding restricted stock units. Each restricted stock unit represents a right to receive one share of Class A Common Stock of the Company. F2: The restricted stock units are fully vested. The Reporting Person has elected, pursuant to the Company's Non-Employee Director Compensation Guidelines (the "Guidelines"), to defer settlement of such restricted stock units until the first to occur of (1) a change in control, (2) the death or permanent disability of the Reporting Person, or (3) the first July 1 following the date of the Reporting Person's termination of service (other than due to death or permanent disability).
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	10,166.3121	Reported balance After 2026-08-25 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-08-25 · Grant · Acquired 52.9246 · Balance 10,166.3121 F1: Reflects restricted stock units received pursuant to dividend equivalent rights accrued on previously outstanding restricted stock units. Each restricted stock unit represents a right to receive one share of Class A Common Stock of the Company. F3: The restricted stock units are fully vested. The Reporting Person has elected, pursuant to the Company's Guidelines, to defer settlement of such restricted stock units until the first to occur of (1) a change in control, (2) the death or permanent disability of the Reporting Person, or (3) in three equal installments on July 1 in the first, second and third years following the date of the Reporting Person's termination of service (other than due to death or permanent disability).
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	4,192.8273	Reported balance After 2026-08-25 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-08-25 · Grant · Acquired 21.8273 · Balance 4,192.8273 F4: Reflects restricted stock units received pursuant to dividend equivalent rights accrued on previously outstanding restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company. F5: The restricted stock units will vest fully on June 2, 2027. The Reporting Person has elected, pursuant to the Company's Guidelines, to defer settlement of such restricted stock units until the first to occur of (1) a change in control, (2) the death or permanent disability of the Reporting Person, or (3) in three equal installments on July 1 in the first, second and third years following the date of the Reporting Person's termination of service (other than due to death or permanent disability).

Filing footnotes · ownership attribution and instrument terms

F1: Reflects restricted stock units received pursuant to dividend equivalent rights accrued on previously outstanding restricted stock units. Each restricted stock unit represents a right to receive one share of Class A Common Stock of the Company.

F2: The restricted stock units are fully vested. The Reporting Person has elected, pursuant to the Company's Non-Employee Director Compensation Guidelines (the "Guidelines"), to defer settlement of such restricted stock units until the first to occur of (1) a change in control, (2) the death or permanent disability of the Reporting Person, or (3) the first July 1 following the date of the Reporting Person's termination of service (other than due to death or permanent disability).

F3: The restricted stock units are fully vested. The Reporting Person has elected, pursuant to the Company's Guidelines, to defer settlement of such restricted stock units until the first to occur of (1) a change in control, (2) the death or permanent disability of the Reporting Person, or (3) in three equal installments on July 1 in the first, second and third years following the date of the Reporting Person's termination of service (other than due to death or permanent disability).

F4: Reflects restricted stock units received pursuant to dividend equivalent rights accrued on previously outstanding restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of the Company.

F5: The restricted stock units will vest fully on June 2, 2027. The Reporting Person has elected, pursuant to the Company's Guidelines, to defer settlement of such restricted stock units until the first to occur of (1) a change in control, (2) the death or permanent disability of the Reporting Person, or (3) in three equal installments on July 1 in the first, second and third years following the date of the Reporting Person's termination of service (other than due to death or permanent disability).

LAM RESEARCH CORP

Report date November 07, 2025 · Filed November 10, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	9,135	Reported balance After 2025-11-07 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-11-07 · Grant · Acquired 1,635 · Balance 9,135 F1: The amount reported includes shares subject to unvested restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: The amount reported includes shares subject to unvested restricted stock units.

MERRIMACK PHARMACEUTICALS INC

Report date June 13, 2018 · Filed June 15, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.67 · Expires 2028-06-12	Direct	7,000	Reported balance After 2018-06-13 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-06-13 · Grant · Acquired 7,000 · Balance 7,000 F1: This option vests as to 1/4th of the total number of shares on 9/13/18 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 6/13/19, provided that such option shall vest in full on the date that is one business day prior to the date of the issuer's next annual meeting of stockholders (if earlier than 6/13/19).

Filing footnotes · ownership attribution and instrument terms

F1: This option vests as to 1/4th of the total number of shares on 9/13/18 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 6/13/19, provided that such option shall vest in full on the date that is one business day prior to the date of the issuer's next annual meeting of stockholders (if earlier than 6/13/19).

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Syneos Health, Inc.

Report date September 28, 2023 · Filed September 28, 2023

Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2023-09-28 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2023-09-28 · Disposition to issuer · Disposed 22,629 · Balance 4,863 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Row 2 · 2023-09-28 · Disposition to issuer · Disposed 4,863 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.

F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,

F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
July 06, 2020 Filed Jul 8, 2020 17:04 UTC	Syneos Health, Inc. SYNH · Entity 109360	PurchaseClass A Common Stock	8,691	$59.11	$513,725.01	Disclosure SEC source: 0001209191-20-041771 · doc4.xml · nonDerivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,426 F1 · shares: Represents shares acquired pursuant to a 10b5-1 trading plan. Read SEC document
June 02, 2020 Filed Jun 4, 2020 22:53 UTC	COGNIZANT TECHNOLOGY SOLUTIONS CORP CTSH · Entity 473	GrantRestricted Stock Units · Derivative	3,939	$0.00	$0.00	Disclosure SEC source: 0001209191-20-034551 · doc4.xml · derivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,939 Underlying: Class A Common Stock · 3,939 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of Cognizant Technology Solutions Corporation (the "Company"). F2 · derivative.exercise_date: The RSUs will vest fully on June 2, 2021. F3 · derivative.exercise_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company, (ii) the reporting person's death or permanent disability or (iii) the first July 1 following the date the reporting person terminates service with the Company. F2 · derivative.expiration_date: The RSUs will vest fully on June 2, 2021. F3 · derivative.expiration_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company, (ii) the reporting person's death or permanent disability or (iii) the first July 1 following the date the reporting person terminates service with the Company. Read SEC document
May 27, 2020 Filed May 29, 2020 17:06 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	2,803	$62.43	$174,991.29	Disclosure SEC source: 0001610950-20-000105 · wf-form4_159078640005739.xml · nonDerivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,735 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
June 04, 2019 Filed Jun 6, 2019 20:04 UTC	COGNIZANT TECHNOLOGY SOLUTIONS CORP CTSH · Entity 473	GrantRestricted Stock Units · Derivative	3,436	$0.00	$0.00	Disclosure SEC source: 0001209191-19-035034 · doc4.xml · derivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,436 Underlying: Class A Common Stock · 3,436 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A Common Stock of Cognizant Technology Solutions Corporation (the "Company"). F2 · derivative.exercise_date: The restricted stock units vest fully on June 4, 2020. F3 · derivative.exercise_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company, (ii) the reporting person's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates service with the Company. F2 · derivative.expiration_date: The restricted stock units vest fully on June 4, 2020. F3 · derivative.expiration_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company, (ii) the reporting person's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates service with the Company. Read SEC document
May 24, 2019 Filed May 29, 2019 16:02 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	4,122	$42.45	$174,978.90	Disclosure SEC source: 0001610950-19-000024 · wf-form4_155916016023323.xml · nonDerivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,932 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
December 10, 2018 Filed Dec 11, 2018 16:09 UTC	Syneos Health, Inc. SYNH · Entity 109360	GrantClass A Common Stock	1,630	$0.00	$0.00	Disclosure SEC source: 0001610950-18-000044 · wf-form4_154456253017744.xml · nonDerivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,810 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document
June 13, 2018 Filed Jun 15, 2018 16:32 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	GrantStock Option (right to buy) · Derivative	7,000	$0.00 Strike: $9.67	$0.00	Disclosure SEC source: 0001209191-18-038075 · doc4.xml · derivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,000 Underlying: Common Stock · 7,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: This option vests as to 1/4th of the total number of shares on 9/13/18 and an additional 1/4th of the total number of shares at the end of each successive three month period thereafter until 6/13/19, provided that such option shall vest in full on the date that is one business day prior to the date of the issuer's next annual meeting of stockholders (if earlier than 6/13/19). Read SEC document
June 05, 2018 Filed Jun 7, 2018 19:14 UTC	COGNIZANT TECHNOLOGY SOLUTIONS CORP CTSH · Entity 473	GrantRestricted Stock Units · Derivative	2,726	$0.00	$0.00	Disclosure SEC source: 0001209191-18-036275 · doc4.xml · derivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,726 Underlying: Class A Common Stock · 2,726 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest fully on June 5, 2019. F3 · derivative.exercise_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company, (ii) the reporting person's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates service with the Company. F2 · derivative.expiration_date: The restricted stock units vest fully on June 5, 2019. F3 · derivative.expiration_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company, (ii) the reporting person's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates service with the Company. Read SEC document
September 13, 2017 Filed Sep 15, 2017 16:40 UTC	MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770	GrantStock Option (right to buy) · Derivative	7,500	$0.00 Strike: $13.99	$0.00	Disclosure SEC source: 0001209191-17-052999 · doc4.xml · derivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-09-12 F1 · derivative.exercise_date: This option is fully vested. Read SEC document
June 07, 2017 Filed Jun 9, 2017 20:28 UTC	COGNIZANT TECHNOLOGY SOLUTIONS CORP CTSH · Entity 473	GrantRestricted Stock Units · Derivative	3,136	$0.00	$0.00	Disclosure SEC source: 0001209191-17-038888 · doc4.xml · derivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,136 Underlying: Class A Common Stock · 3,136 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's Class A Common Stock. F2 · derivative.exercise_date: The restricted stock units vest fully on June 7, 2018. F3 · derivative.exercise_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company (ii) the Director's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates employment with the Company. F2 · derivative.expiration_date: The restricted stock units vest fully on June 7, 2018. F3 · derivative.expiration_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company (ii) the Director's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates employment with the Company. Read SEC document
April 01, 2017 Filed Apr 4, 2017 20:00 UTC	COGNIZANT TECHNOLOGY SOLUTIONS CORP CTSH · Entity 473	GrantRestricted Stock Units · Derivative	400	$0.00	$0.00	Disclosure SEC source: 0001209191-17-024655 · doc4.xml · derivative · entry 2 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400 Underlying: Class A Common Stock · 400 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Company's Class A Common Stock. F3 · derivative.exercise_date: The restricted stock units vest in three equal annual installments beginning on April 1, 2018. F4 · derivative.exercise_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company (ii) the Director's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates employment with the Company. F3 · derivative.expiration_date: The restricted stock units vest in three equal annual installments beginning on April 1, 2018. F4 · derivative.expiration_date: Vested shares will be delivered to the reporting person upon the earliest to occur of (i) a "change in control event" of the Company (ii) the Director's death or permanent disability or (iii) on July 1 following the year in which the reporting person terminates employment with the Company. Read SEC document
April 01, 2017 Filed Apr 4, 2017 20:00 UTC	COGNIZANT TECHNOLOGY SOLUTIONS CORP CTSH · Entity 473	GrantClass A Common Stock Option (Right to Buy) · Derivative	1,827	$0.00 Strike: $59.52	$0.00	Disclosure SEC source: 0001209191-17-024655 · doc4.xml · derivative · entry 1 Dineen John M. · CIK 0001645270 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827 Underlying: Class A Common Stock · 1,827 shares Expires 2024-04-01 F1 · derivative.exercise_date: The options vest in two equal annual installments beginning on April 1, 2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.